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ABSTRACT 
In this study retinoic acid (RTA) loaded solid lipid nanoparticles (SLNs) optimized by tuning 
the process parameters (pressure/temperature) and using different lipids to develop 
nanodispersions with enhanced anticancer activity. The RTA-SLN dispersions were produced 
by high-pressure homogenization and characterized in terms of particle size, zeta potential, 
drug entrapment efficiency, stability, transmission electron microscopy (TEM), atomic force 
microscopy (AFM), X-ray diffraction (XRD) and in vitro drug release. Thermal and X-ray 
analysis showed the RTA to be in the amorphous state, whilst microscopic images revealed a 
spherical shape and uniform particle size distribution of the nanoparticles. Anticancer 
efficiency was evaluated by incubating RTA-SLNs with human prostate cancer (LNCap) 
cells, which demonstrated reduced cell viability with increased drug concentrations (9.53% at 
200 ug/ml) while blank SLNs displayed negligible cytotoxicity. The cellular uptake of SLN 
showed localization within the cytoplasm of cells and flow cytometry analysis indicated an 
increase in the fraction of cells expressing early apoptotic markers, suggesting that the RTA 
loaded SLNs are able to induce apoptosis in LNCap cells. The RTA-SLN dispersions have 
the potential to be used for prostate anticancer treatment. 
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1. Introduction 
Solid lipid nanoparticles (SLNs) have attracted increasing attention as a promising 
colloidal carrier system, especially for lipophilic drugs (Chen et al., 2001; Mehnert et al., 
2001; Müller et al., 2004; Castelli et al., 2005). SLNs are spheres or platelets in the 
submicron size range (mainly between 150 and 300 nm). These are made of lipids, which are 
solid at room and body temperature and dispersed in an aqueous medium (Müller et al., 
2011; Battaglia and Gallarate., 2012). SLNs are composed of a high melting point lipid as a 
solid core, which is coated by surfactants. Therefore, lipophilic drugs can be efficiently 
incorporated in the lipid core of SLNs. SLNs consist of a solid core rather than a fluid core, 
such as liposomes and emulsions, which facilitates prolonged and controlled release of drugs 
(Mehnert et al., 2001). SLN incorporated drugs are protected against chemical degradation 
(Lim et al., 2002). The production of SLNs is easier to scale up compared with other drug 
delivery systems such as polymeric nanoparticles or liposomes (Mueller et al., 2000). The 
advantages of SLNs have driven numerous studies with various applications, particularly for 
parenteral administration of drugs. Typical parenteral SLNs applications include intra-
articular to intravenous peroral administration (Muller et al., 2000) increased drug solubility 
(Yang et al., 2014) and pulmonary delivery (Yang et al., 2012). Studies performed by Gasco 
et al., revealed that intravenously administered SLNs display prolonged drug plasma levels. 
Moreover, a much lower uptake by liver and spleen macrophages occurs due to the low 
surface hydrophobicity of SLNs avoiding the absorption of any blood proteins (Gasco et al., 
1993; Goppert and Muller, 2005). 
Retinoic acid (RTA) is a promising anticancer agent, which has been investigated in 
chemoprevention and treatment of cancer (Orlandi et al., 2002; Carneiro et al., 2012). The 
anticancer properties of RTA are achieved by binding to retinoic acid receptors or retinoid X 
receptors present on the nuclear membrane of cancer cells, leading to the induction of growth 
inhibition, differentiation or apoptosis in these cells (Fang et al., 2002). RTA has already 
been used in clinical trials where RTA was given to cancer patients by oral administration, 
though the RTA concentration in blood circulation gradually decreases after long-term oral 
treatment. This phenomenon might occur due to the induced cytochrome P-450-dependent 
metabolism of RTA (Muindi et al., 1992). The poor aqueous solubility of RTA can be a 
major drawback for its parenteral administration. However, the incorporation of RTA in 
lipid-based carriers such as SLNs could be an attractive means to overcome such solubility 
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limitations. The aim of this study was to develop stable RTA-SLN formulations with 
improved cellular uptake and anticancer efficacy in prostate LNCaP cancer cells.  
 
2. Materials and methods  
2.1. Materials 
Retinoic acid was purchased from TCI (UK). Precirol® ATO 5 (PR) was purchased from 
Gattefosse. Poloxamer 188 (P188) was kindly donated by BASF (Ludwigshafen, Germany). 
LNCap cell line was purchased from the American Type Culture Collection (ATTC, 
Manassa, Virginia, USA). Stearic acid (SA), tristearin (TS), trilaurin (TL), 'XOEHFFRµV
PRGLILHG(DJOHµVPHGLXP'0(0WKLD]RO\OEOXHWHWUD]ROium bromide (MTT), L-glutamine, 
penicillin, streptomycin, heat inactivated fetal bovin serum (FBS) and trypsin were purchased 
from Sigma-Aldrich (UK). Rhodamine was purchased from Avanti polar lipids (USA). PE 
Annexin V Apoptosis Detection Kit I containing 7AAD as vital stain was obtained from BD 
Biosciences, UK. All the other chemicals and solvents used were of analytical or high-
performance liquid chromatography (HPLC) grade. 
 
2.2. Preparation of SLNs 
SLNs were prepared by high pressure homogenization. In brief, appropriate amounts 
of lipids e.g., SA and P188 were accurately weighed and heated above the melting point of 
the lipid. For RTA loaded SLNs the drug was separately dissolved in ethanol (3 ml) and then 
added to the molten lipid. The drug containing the melted lipid was dispersed in a hot 
aqueous phase and homogenized with an UltraTurrax T25 (IKA®- WERKE GMBH, Staufen, 
Germany) homogenizer to form a pre-emulsion. The coarse dispersion produced was then 
transferred and homogenized in a Micro DeBee (South Easton, MA, USA) high pressure 
homogenizer at 15,000 psi for 7 min at 70°C. The hot nano-dispersions were left to cool and 
allow the lipid to crystallize by forming lipid nanoparticles with a solid matrix.  
 
2.3. Particle size analysis and zeta potential 
The particle size distribution and zeta potential of the produced preparations were 
determined by dynamic light scattering photon correlation spectroscopy (PCS) using a 
Malvern Zetasizer Nano-ZS (Malvern, UK). The dispersion were adequately diluted with 
distilled water and measured in triplicate. The z-average and the PDI were applied for the 
evaluation of the particle size. The particle size range determined was 0.6 nm-6 µm. 
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2.4. Atomic force microscopy 
For AFM experiments, 3 µL of RTA loaded and unloaded SLN were deposited onto a 
freshly cleaved mica surface ((G250-2 mica sheets 1" x 1" x 0.006"; Agar Scientific Ltd, 
Essex, UK), and left to dry for 1 h before AFM imaging. The images were obtained by 
scanning the mica surface, in air, under ambient conditions using a PeakForce QNM 
Scanning Probe Microscope (Digital Instruments, Santa Barbara, CA, USA; Bruker 
Nanoscope analysis software Version 1.40). The AFM measurements were obtained using 
ScanAsyst-air probes, and the spring constant (0.67 N/m; nominal 0.4 N/m) and deflection 
sensitivity were calibrated, but not the tip radius (a nominal value of 2 nm was used). Surface 
roughness (Ra) values were determined by entering surface scanning data into a digital 
levelling algorithm (Bruker Image Analysis Nanoscope Analysis software V 1.40). AFM 
images were collected from two different samples by random spot surface sampling (at least 
five areas).  
 
2.5. Transmission electron microscopy (TEM) 
The shape and size of the SLN dispersions were investigated by TEM. Before 
analysis, the samples were diluted 1:2 and stained with 2% (w/v) phosphotungstic acid for    
30 s and placed on copper grids with films for observation. After 1 min of absorption, excess 
liquid was blotted off with filter paper. The dried specimens were examined by using a 
Hitachi SH 8030 microscope. The electron beam was accelerated with a voltage of 10 kV. 
The SEM images were captured using a Gatan, Inc. ORIUS SC200 CCD Camera. Several 
magnification levels were used. 
 
2.6. Lyophilisation of SLNs  
The empty and RTA loaded SLN dispersions were freeze-dried without the addition 
of cryoprotectants using an Advantage freeze-dryer (Biopharma process systems, UK). The 
lyophilisation process was carried out by cooling the samples from 20°C to -50°C at 
0.5°C/min under atmospheric pressure and samples were held at -50°C for 2 hr. After 2 hr the 
pressure was reduced to 30 mTor, the sample plates were heated to -10°C and the samples 
were dried under the aforementioned conditions for 48 hr. Afterwards the plates were slowly 
heated at 0.2°C/min to 20°C and the pressure reduced to 10 mTor for 2 hr to remove residual 
water 
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2.7. X-ray powder diffraction 
Samples of bulk RTA, empty SLNs and RTA-SLN formulations were evaluated using 
a Bruker D8 Advance (Coventry, UK) diffractometer in theta-theta mode, Cu anode at 40 kV 
and 40 mA, parallel beam Goebel mirroe, 0.2 mm exit slit, Lynxeye position sensitive 
detector (PSD) with a 3° opening and LynxIris at 6.5 mm, sample rotation at 15 rpm. The 
sample was scanned from 2 WRșZLWKDVWHSVL]HRI șDQGDFRXQWLQJ WLPHRI    
0.2 s per step; 176 channels active on the PSD making a total counting time of 35.2 s per step. 
 
2.8. Differential scanning calorimetry (DSC) 
DSC measurements of bulk RTA, empty SLNs and RTA-SLN formulations were 
conducted using a Mettler Toledo DSC 823 instrument (Schwerzenbach, Switzerland). 
Approximately, 3-5 mg samples were accurately weighed in standard aluminium pans. An 
empty pan was used as a reference. A scan rate of 10°C/min was employed to heat the 
samples from 20 to 220°C. Analysis was performed under a nitrogen purge (60 mL/min). 
Calorimetric parameters were analysed using STARe Software.  
 
2.9. Determination of encapsulation efficiency 
The drug loading (DL) and encapsulation efficiency (EE) was estimated according to 
Potta et al., (2011). In brief, 1 ml of SLN nano-suspension was centrifuged at 40,000 rpm, for 
30 min at 25°C. The pellets of RTA loaded SLNs were then dissolved in acetonitrile and the 
absorbance of the dissolved pellets were measured after appropriate dilutions. The DL and 
encapsulation efficiency (EE%) were calculated by using Equations (1) and (2), respectively.  
 ܦݎݑ݃݈݋ܽ݀݅݊݃ ൌ  ஺௠௢௨௡௧௢௙ோ்஺௜௡ௌ௅ே௦஺௠௢௨௡௧௢௙ௌ௅ே௦ ൈ  ? ? ?                                          (1) ܧ݊ܿܽ݌ݏݑ݈ܽݐ݅݋݊݂݂݁݅ܿ݅݁݊ܿݕ ൌ  ܦݎݑ݃݈݋݄ܽ݀݅݊݃ܶ݁݋ݎ݁ݐ݈݅ܿܽ݀ݎݑ݃݈݋ܽ݀݅݊݃ ൈ  ? ? ?ሺ ?ሻ 
 
 
 
2.10. Drug release properties of RTA-SLNs 
A dispersion of SLNs (1 ml) was transferred into a cellulose dialysis bag (molecular 
weight cut-off: 10,000 Da), which was then suspended in a beaker containing a mixture of 
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double-distilled water and ethanol (50:50, v/v) as the dissolution medium (Liu et al., 2007). 
The beaker was then placed in a shaker bath at a temperature of 37°C. At various time 
intervals the dissolution medium (20 ml) was replaced and the drug content was analysed by 
UV spectroscopy using DȜPD[ of 340 nm. 
 
2.11. Cytotoxicity tests  
LNCap prostate cancer cell lines were cultured in DMEM medium supplemented with 
10% serum, 1X L-glutamine/penicillin streptomycin (Sigma, UK) at 37°C and 5% CO2. The 
culture medium was changed every three days. The cytotoxicity of RTA loaded SLNs and 
pure RTA (dissolved in ethanol) was determined in the LNCap prostate cancer cell line using 
the MTT assay. Cells were seeded in a 24 well flat-bottom plates at a cell density of 1 × 106 
cells/well in 1 ml DMEM and incubated for 24 hr.  The SLN formulations, (empty, loaded), 
pure RTA and ethanol were then added into the 24 well plates at various concentrations for 
different incubation times (24, 48 hr). Pure RTA was solubilized in ethanol (10 mg/ml) and 
incubated at concentrations of 10, 20, 50, 100, 200 µg/ml.  At the end of the incubation time 
ȝ/RI077VROXWLRQPJPOZDVDGGHGWRHDFKZHOODQGLQFXEDWHd at 37°C for another 
2 hr. The culture medium was then discarded and ȝORIDFLGLILHGLVRSURSDQROwas added 
in order to GLVVROYH WKH 077 IRUPD]DQ FU\VWDOV $ WRWDO RI  ȝ/ RI WKH GLVVROYHG 077
formazan crystals were transferred into a 96 well flat-bottom plate and the absorbance read at 
492 nm using a microplate reader. Controls included non-treated cells and ethanol (2%) for 
the pure drug cytotoxicity assay. Blank (unloaded) and loaded SLN formulations were 
incubated and the cytotoxicity of blank and loaded SLN formulations were also tested on 
LNCap cells. Concentrations of blank SLNs were kept between 0.18, 0.37, 0.73, 1.11, 1.47 
and 2.94 mg/ml while loaded SLN formulations had drug (RTA) concentrations of 12.5, 25, 
50, 75, 100 and 200 µg/ml.   
 
2.12. Cellular uptake by fluorescent microscopy 
Samples for microscopic analysis were prepared via seeding 2 × 104 cells/well on 
cover slips in a 24 well flat-bottom plate. Empty rhodamine (10 ȝJ mg of lipid) stained 
SLN formulations were incubated with the cells for 24 hr at various concentrations. The cell 
medium was discarded from the well after the incubation and washed three times with PBS;   
1 ml of 4% para-formaldehyde was added to each well to fix the cells on the cover slips and 
left in the dark for 15 min. The para-formaldehyde was discarded from the well and cells 
were washed three times with PBS and then mounted on a glass slide using vectashield 
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mounting medium containing DAPI. The cover slips were sealed on a glass slide with a nail 
polish and left to dry. Images were acquired using the Nikon ECLIPSE 90i overhead 
epifluorescent microscope attached to a Nikon digital camera (DS-Qi1Nc) and a computer 
running Nikon NIS-Elements Advanced Research software. The principal objective used for 
fluorescent imaging was an oil immersion CFI Plan Apochromat VC 60X N2 (NA1·4, WD 
0·13 mm). 
 
2.13. In vitro apoptosis studies 
Apoptosis is a form of cell death that plays an important role during development, 
normal tissue homeostasis and is deregulated in many diseases, including cancer. The effect 
of apoptosis in LNCap prostate cancer cell lines was studied by flow cytometry. The early 
stages of apoptosis were detected following staining with a PE Annexin V Apoptosis 
Detection Kit I containing 7AAD as vital stain. The cells were seeded in 24 well flat-bottom 
plates at a cell density of 1 × 106 cells/well and incubated for 24 hr. SLN formulations, 
(empty, loaded) and pure RTA (25 ug/ml) were added to each well. Untreated cells were used 
as negative controls. After 48 hr, cells were stained according to the manufacturer¶V protocol. 
Samples were analysed on by using a Accuri C6 flow cytometer for PE and 7AAD 
expression using a solid state blue laser with a 488 nm excitation spectrum and a detector of 
FL1 path with a 530/30 nm filter. A minimum of 10000-gated events was acquired from the 
cell population and data analysed using the Accuri C6 software. Cells were considered early 
apoptotic when PE positive and 7AAD negative; late apoptotic/early necrotic when PE 
positive and 7AAD positive. All experiments were performed in triplicate and repeated three 
times. 
  
2.14. Statistical analysis 
Results were expressed as means and standard deviation of the mean (n=3). Statistical 
significance was also determined by t-test analysis for comparison between RTA loaded SLN 
and blank SLN formulations on the LNCap prostate cancer cell line. Differences were 
considered as significant when the P-value was < 0.05 
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3. Results and discussion 
3.1 Particle size distribution and zeta potential  
The particle size and zeta potential of blank 6/1¶Vprepared by using various lipids 
was investigated by using the same lipid/surfactant ratios, as shown in Fig. 1 and Table 1. 
Laser diffraction analysis showed monomodal particle size distribution for all dispersions 
with sizes varying from 140 ± 150 nm and polydispersity indexes of less than 0.22.  It is 
obvious that the nature of the lipid did not affect the particle sizes obtained for the SLNs. 
Similarly the zeta potential varied between -13 to -19 mV, which is an indication of long-
term stability as the higher zeta potential values indicate high electric charge on the surface of 
the SLNs, which induces strong repulsion forces between the particles preventing aggregation 
of the SLN dispersions (Yousefi et al., 2009).  Indeed SLN dispersions were stable over six 
months with a slight increase in the particle size varying from 10 ± 20 nm (data not shown).  
RTA loaded SLNs of the same lipids were then prepared by high-pressure 
homogenisation at temperatures above the lipid melting point. However, during the process 
optimization it was observed that RTA-SLNs prepared with TL and PR were very unstable 
followed by drug precipitation within a few hours even at low drug loadings and thus further 
evaluation of RTA-SLNs with these two lipids was not possible. The loaded SLN dispersions 
prepared using TS and SA displayed far better stability and were further evaluated. RTA-
SLNs prepared by using TS as the core lipid showed an average particle size of 255.9 nm and 
zeta potential of -0.05 mV but appeared to be unstable during long term stability. After six 
months, RTA recrystallization was observed and a second particle size peak at 3.3 µm 
appeared, as shown in Fig. 2. 
In contrast RTA±SLNs prepared by using SA as the core lipid showed a narrow 
monomodal particle size distribution with a z-average diameter of 232.3±3.1nm and a zeta 
potential of -8.55±1.71 mV. As shown in Table 2 for the RTA loaded SLNs, a significant 
particle size increase was observed compared to the empty dispersions of the same lipids. 
This increase can be attributed to drug incorporation in the lipid nanospheres.  In addition, 
RTA can cause significant increase in the viscosity resulting in an increase in particle size 
(Padhye et al., 2013).  
3.2 TEM and AFM morphology of SLNs 
Fig. 3 shows the TEM images of empty and RTA loaded SLNs, which appear to be 
spherical with a uniform particle size distribution. However, the SLN particle size in the 
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TEM images appears to be between 50-60 nm, which is not in good agreement with the 
results obtained from the laser diffraction measurements. The reasons for the different 
particle sizes are due to the following two reasons: a) laser diffraction measures the 
³K\GURdynamic GLDPHWHU´ ZKLFK depends on the surface structure and not only on the 
SDUWLFOH ³FRUH´ DQG E for the TEM analysis, SLNs were stained with 2% (w/v) 
phosphotungstic acid and subsequently dried which probably caused significant shrinkage of 
the lipid particles (Liu et al., 2007). For this reason AFM analysis, which can identify 
material properties at high resolution across a topographic image, was used to measure the 
SLN particle size. The overall particle diameter (estimated from the width of the peak at the 
baseline in section height profiles), for both empty and loaded SLN dispersions was 
estimated, as shown in Fig. 4. AFM analysis revealed spherical shaped nanoparticles with 
particle sizes of 117.8 ±11.0 nm and 169.8 ±21.0 nm for empty and loaded SLNs, 
respectively. The results obtained from the AFM imaging are similar to those from the laser 
diffraction measurements but with slightly smaller particle diameters. Again the reason for 
the observed smaller particle sizes is that SLNs were absorbed on the mica surface and 
underwent a drying process, which might have contributed to the size deformation (Jung et 
al., 2006). Moreover, in AFM studies there is a slight flattening of the SLNs which might also 
be responsible for the small difference between the diameter and the height of nanoparticles 
(Dubes et al., 2003). 
 
3.3. Physicochemical characterization 
The physical state of bulk materials, empty SLNs and RTA-SLNs was evaluated by 
XRD analysis. The empty and drug loaded dispersions were freeze-dried prior to the X-ray 
analysis. As shown in Fig. 5 the diffractograms of bulk SA and RTA displayed characteristic 
sharp peaks at 6.63°, 11.1°, 21.55°, 24.15° and 5.19°, 13.52°, 14.71°, 15.56°, 20°, 20.8°, 
22.81°, 24.98°, 24.98°, 26.15°, 27.23° 2T values, respectively which indicated the crystalline 
nature of both materials.  Similarly P188 presented intensity peaks at 19.17°, 23.36° 2T 
values. In Fig. 6 it is evident that the less ordered crystals of SA are present in both empty 
and loaded SLNs, where the majority of the intense peaks are not present. Likewise no high 
intensity peaks for RTA could be detected for the drug loaded SLNs suggesting that RTA is 
entrapped within the lipid core in an amorphous form (Mulik & Monkkonen, 2010).  
DSC thermal analysis of bulk SA, P88, RTA empty and loaded SLNs (Fig. 7) were 
conducted in order to further investigate the physical state of the colloidal lipid matrices. The 
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bulk SA, P188 and RTA presented endothermic melting peaks at 69.82°C, 51.81°C and 
167.80°C, respectively. The SLN formulations showed two distinct melting endothermic 
peaks at 49°C and 66.49°C, which are attributed to the surfactant and the lipid, respectively. 
The melting endotherms of empty SLNs appeared broad and less sharp compared to the bulk 
substances indicating an increased number of lattice defects (Siekmann et al., 1994).  In 
addition, the melting peaks for both empty and loaded SLNs were shifted to lower 
temperatures indicating possible surfactant-lipid interactions (Padhye et al., 2013).  For the 
RTA-SLNs the melting endotherm of RTA could not be observed suggesting, again, that the 
drug is in an amorphous state. However, RTA could have been completely solubilised in the 
lipid matrix due to the melting of drug in lipid (Padhye et al., 2013). In another study Mulik 
et al. (2012) proposed that these findings indicate the entrapment of RTA within the 
nanoparticles in a molecularly dispersed form.  
3.4. Determination of EE and DL  
RTA-SLNs prepared either with SA or TST as the core lipid demonstrated EE of 90% 
suggesting very high drug entrapment in the nanoparticles. As RTA is very hydrophobic the 
stability of the drug within the lipid matrix is considered to be the key factor underlying drug 
encapsulation within the SLN (Chinsriwongkul et al., 2011). According to Tiyaboonchai et 
al., (2007) addition of surfactant in SLN dispersions plays a key role in enhancing the drug 
loading efficiency. In the developed SLN dispersions P188 was used as a surfactant, where 
the estimated DL observed was 6.2 %. Nevertheless, the DL was not very high as RTA 
started precipitating immediately when drug loading was increased.  
 
3.5. Drug release studies 
As shown in Fig. 8, RTA-SLN formulations presented a biphasic in vitro drug release 
pattern. A burst release was observed for the first 10 hr where almost 40% of the drug was 
released, followed by sustained release for five days. The initial burst release characteristics 
indicates that some drug molecules were adsorbed on the surface of the SLN particles, while 
the sustained release pattern suggests drug diffusion from the core of the lipid matrix (Sun et 
al., 2013). According to Nayak et al., (2010) the drug release patterns from the lipid core 
depends greatly on the crystallinity of the lipid matrix. As shown from the XRD and thermal 
analysis results, RTA loaded SLN dispersions showed less ordered crystals of the lipid 
matrix, which facilitates faster drug elution from the SLNs. 
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3.6. Cytotoxicity of RTA and SLN formulations  
The cytotoxicity of bulk RTA, empty and RTA loaded SLN was evaluated in LNCaP 
prostate cancer cells by using the MTT assay.  The RTA cyctotoxicity was extrapolated by 
comparison with alcoholic solutions and loaded SLNs.  According to Serpe et al., (2004), 
SLNs can enter cancer cells, which should facilitate the anticancer activity of the drug when 
encapsulated in the lipid core.  
RTA a potent anticancer agent showed strong cytotoxicity on LNCap cell lines at a 
concentration of 20 µg/ml, where the cell viability was reduced to 59.3% after 24 hr 
incubation (Fig. 9). The RTA cytotoxicity increased with the drug concentration and at         
50 µg/ml the viability was reduced to 46.8% while a further increase to 200 µg/ml of RTA 
resulted in a cell viability of 9.5%. This observation is in agreement with previous data on the 
effect of RTA on prostate cancer cells (McCormick et al., 1999).  
As shown in Fig. 9 (inset) the cytotoxicity of empty SLNs with SA as the core lipid 
was evaluated in order to confirm any significant loss in cell viability. The results showed 
negligible cytotoxicity with 90% cell viability at 3 mg/ml of SLN dispersions.  
The effect of increase in RTA concentration on cell viability was assessed by the 
MTT assay (Fig. 10). It was found that with RTA-SLNs the toxic effect was dose dependent. 
At the lowest drug concentration tested of 12.5 µg/ml cell viability decreased to 88.6% while 
remaining significantly higher in control cells treated with SLN formulation only (P<0.05). 
With an increasing drug concentration the cytotoxic effect became even more pronounced. At 
a drug concentration of 100 µg/ml a significant difference in cell viability was observed 
between RTA-SLNs and blank SLN formulations, as the cell viability was reduced to 46.8% 
(P<0.001).At an even greater RTA concentration of 200 µg/ml the cell viability was 35.2%. 
The effect of treatment time on the cytotoxicity of RTA-SLN was also investigated. After    
being exposed to cells for 48 hr the RTA-SLNs were significantly more effective than after 
treatment for 24 hr, as the cell viability was 19.8% at an RTA concentration of 200 µg/ml. 
The time dependent increase in the cytotoxic effect suggests that more drug is released from 
the lipid matrix indicating sustained release effect of RTA-SLN.  These findings also show 
that free RTA (Fig. 10) is significantly more anti-proliferative than RTA-SLN. As the blank 
SLNs do not induce any significant effect on cell viability, the effect of encapsulated RTA on 
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3.7. Cellular internalisation and in vitro apoptosis 
SLNs are known to enter cells via endocytosis (Kang et al., 2010). In order to confirm 
the internalization of the SLN formulation, rhodamine containing SLNs were incubated with 
LNCap cells and cellular uptake visualised via fluorescent microscopy after staining the 
nucleus of the cells with DAPI. Internalization of SLN formulations was observed after 24 hr. 
SLN particles were localised in the cytoplasm around the cell nucleus, as illustrated in        
Fig. 11. 
The induction of apoptosis by both pure RTA and within SLNs at different 
concentrations was detected and quantified by flow cytometry (Fig. 12). Cells treated with 
pure RTA (25 µg/ml) showed that 24.3% of the whole population was early apoptotic while 
20% was late apoptotic/ early necrotic. Similarly, when treated with RTA-SLN at 25 µg/ml 
27.4% were early apoptotic and 17.7% were late apoptotic/ early necrotic. These results 
VXJJHVW WKDW OLNH SXUH 57$ 57$ ORDGHG 6/1¶V DOVR LQGXFHG apoptosis. At higher 
concentrations of both treatments an increase in the fraction of late apoptotic/early necrotic 
cells was found (Fig. 12). 
The increase in the percentage of late apoptotic/early necrotic cells following 
treatment clearly linked RTA and RTA loaded SLNs which appeared to be significantly 
higher when compared to untreated cells (P<0.05). This increasing population of late 
apoptotic/early necrotic cells with higher concentration confirmed that enhanced cytotoxicity 
of RTA-6/1¶Vwas dose dependant. Experiments with control (blank SLN treated cells) and 
untreated cells showed negligible effects in terms of inducing the apoptotic pathways, as no 
significant alteration were observed in both early apoptotic and late apoptotic/early necrotic 
cell populations.  
 
4. CONCLUSIONS 
In the current study SLN dispersions were prepared by HPH and loaded with the 
anticancer agent RTA.  Drug loaded SLNs presented good stability only when SA was used 
as a core lipid.  The dispersions showed high EE with biphasic release where the initial burst 
release was followed by a sustained pattern. The anticancer activity of RTA-SLNs was 
assessed in LNCaP prostate cancer cells and showed a viability of 19.8% at an RTA 
concentration of 200 µg/ml after a 48 hr incubation. Moreover, fluorescent microscopy 
images confirmed the internalisation of SLNs inside the cytoplasm of the cell. In vitro 
apoptosis analysis revealed that upon treating LNCaP cells with RTA-SLNs, 67% of the cells 
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were late apoptotic/early necrotic at a concentration of RTA of 150 µg/ml RTA. Overall the 
optimized RTA-SLN dispersions appear to be a promising drug delivery system for cancer 
treatment.  
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Table 1: Blank SLN dispersions made by using TS, SA, PR and TL (n=3). 
 
 
Table 2: RTA loaded SLN dispersions made using SA and TS (n=3). 
SLNs Lipid Lipid 
(mg) 
P188 
 (mg) 
RTA 
 (mg) 
Particle size  
(nm, ±SD) 
Zeta potential 
(mV, ±SD) 
PI 
 (±SD) 
RTA- TS Tristearin 500 250 50 255.9 ±2.7 -0.06 ± 0.01 0.30 ± 0.09 
RTA- SA Stearic acid 500 250 50 232.3 ±3.1 -8.55 ±1.71 0.21±0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SLNs Lipid Lipid 
(mg) 
P188 
(mg) 
Particle size 
(nm, ±SD) 
Zeta potential 
 (mV, ±SD) 
PI 
 (±SD) 
BL- TS Tristearin 500 250 148.4 ±3.1 -19.20 ±1.61 0.11 ±0.03 
BL- SA Stearic acid 500 250 145.1  ±2.7 -18.74 ±1.77 0.10 ±0.02 
BL- PR Precirol 500 250 143.4 ±1.2 -15.47 ±0.13 0.08 ±0.03 
BL- TL Trilaurin 500 250 149.2 ±5.5 -13.32 ±0.23 0.07 ±0.01 
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FIGURES CAPTION LIST 
Fig. 1. (a) RTA-SA SLN dispersions. (b) Particle size distribution of RTA-SA SLNs (where 
the size quoted is the z-average mean (nm) of the hydrodynamic diameter (nm) of the lipid 
dispersion. (c) Zeta potential (mV) of RTA-SA SLNs. 
 
Fig. 2. (a) RTA-TS SLN dispersions. (b) Particle size distribution of RTA-TS SLNs (where 
the size quoted is the z-average mean (nm) of the hydrodynamic diameter (nm) of the lipid 
dispersion. (c) Zeta potential (mV) of RTA-TS SLNs. 
 
Fig. 3. Transmission electron micrographs of A) BL- SLNs and B) RTA-SLNs. 
Fig. 4. AFM images of blank-SLNs (A, B) and RTA loaded SLNs (C, D). 
Fig. 5. XRD diffractograms of bulk SA, poloxamer 188 and RTA. 
Fig. 6. XRD diffractograms of blank SLN, RTA-SLNs and RTA. 
Fig. 7. DSC thermograms of RTA, SA, P188, BL-SLNs and RTA-SLNs. 
Fig. 8. Drug release profile of SA based SLNs loaded with RTA. 
Fig. 9. a) Anti-proliferative effects of pure RTA on prostate cancer cells (LNCap) using the 
MTT assay for a 24 hr incubation and b) cytotoxicity of stearic acid based blank SLNs (BL-
SLNs), after 24 hours of incubation (inset). 
Fig. 10. Cytotoxicity of stearic acid based RTA loaded SLN (RTA-SLN), after 24 and 48 hr 
incubation. Data is represented as meansS.D. (n = 3). P<0.05, *P< 0.0001, RTA-SLN       
(24 hr) vs. empty SLN and P<0.05, **P< 0.0001, RTA-SLN (48 hr) vs. empty SLN. 
 
Fig. 11. Fluorescent images of the cellular uptake of empty formulated SLN localisation in 
the cytoplasm of the cell. The nucleus of the cell was stained blue with DAPI and the SLN 
formulation was labelled with rhodamine. 
 
Fig. 12. Quantitative apoptotic measurement in LNCap cells after treatment with BL-SLN 
(blank SLN), pure RTA and RTA-SLN (RTA loaded SLN). (A) Dose dependent effect on 
early apoptosis by treatment with a concentration of 25, 75 and 150 µg/ml of RTA-SLNs for 
48 hr, determined by flow cytometry analysis. (B) Dose dependent effect on late apoptosis by 
treatment with a concentration of 25, 75 and 150 µg/ml of RTA-SLNs for 48 hr, determined 
by flow cytometry analysis. The results are expressed as bar chart. Data as mean±S.D., (n = 
3). (*) P< 0.05, Control versus RTA-SLN (25µg/ml), (**) P<0.05, Control versus       RTA-
SLN (75µg/ml), (***) P<0.05, Control versus RTA-SLN (150µg/ml) (C) Dose dependent 
effects are expressed as dot plot of PE AnnexinV versus 7-AAD. Top left: necrotic cells; top 
right: late apoptotic cells/early necrotic cells; bottom left: live cells; and bottom right: early 
apoptotic cells. 
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